5 Best Tech Stocks To Buy For 2014

Royalty Pharma announced Monday that it's willing increase the $11-per-share offer it made for Elan (NYSE: ELN  ) back in February, depending on the result of Elan's buyback.

The biotech recently announced plans to repurchase $1 billion worth of shares through a Dutch auction. As part of the auction, investors are given the option to sell their shares back to the company at a price between $11.25 and $13.00, specified by the shareholder. Elan would then buy back shares at the lowest price that allows it to purchase shares worth $1 billion in aggregate.

Royalty Pharma has tied its offer to the price Elan ends up paying at the Dutch offering. It'll pay the same amount as shareholders were given if the offer is for $11.25 or $11.50. If shareholders demand $11.75 or $12, Royalty Pharma is willing to pay $12 per share for the remaining share of Elan. If shareholders demand more than $12, Royalty Pharma is willing to pay only $11 per share, presumably because it believes at that level Elan is overpaying to buy back its shares.

5 Best Tech Stocks To Buy For 2014: Oracle Financial Services Software Ltd (ORCL.NS)

Oracle Financial Services Software Limited is principally engaged in the business of providing information technology (IT) solutions and knowledge processing services to the financial services industry worldwide. The Company has a suite of banking products, which caters to the needs of corporate, retail, investment banking, treasury operations and data warehousing. The Company operates in three segments: Product licenses and related activities, IT solutions and consulting services, and Business Processing Services (BPO). Product licenses and related activities segment deals with various banking software products. IT solutions and consulting services segment offers services spanning the entire lifecycle of applications used by financial service institutions. The division�� portfolio includes Consulting, Application, Support and Technology Services. BPO Services consists of business process outsourcing services to the Lending, Collections, Customer Service and Capital Mark ets industry.

5 Best Tech Stocks To Buy For 2014: Orbit International Corporation(ORBT)

Orbit International Corp., through its subsidiaries, engages in the design, manufacture, and sale of electronic components and subsystems, and commercial and custom power units. The company operates through two segments, Electronics and Power. The Electronics segment designs, manufactures, and sells customized panels, components, and subsystems for contract program requirements to prime contractors, governmental procurement agencies, and research and development laboratories. Its products include remote control units; intercommunication panels; displays; keyboards, keypads, and pointing devices; operator control trays; command display units; gun computer system cabinets; gun mount control panels; serial data converters; harness assemblies; and system integration products. This segment?s products are deployed in surveillance aircraft, shipboard programs, and land-based guidance control programs. This segment also performs the analysis and evaluation of caliber naval gun we apon systems performance; involves in the design, integration, and production of components for caliber naval gun weapon systems; and offers engineering supplies and services in support of caliber naval gun weapon systems initiatives. The Power segment designs, manufactures, and sells power supplies, AC power sources, frequency converters, uninterruptible power supplies, and associated analytical equipment and other electronic equipment, as well as commercial-off-the-shelf power modules. This segment?s products are used in production lines, engineering labs, oil and gas exploration, aircraft and ships, and related ground support systems. The company markets its products primarily through its direct sales personnel, as well as through manufacturer's representatives and distributors. The company was formerly known as Orbit Instrument Corp. and changed its name to Orbit International Corp. in July 1991. Orbit International Corp. was founded in 1957 and is based in Hauppauge, N ew York.

Hot Insurance Stocks To Own For 2014: Algeta ASA (ALGETA)

Algeta ASA is a Norway-based biotechnology company engaged in the development of targeted cancer therapies based on its alpha-pharmaceutical platform. The Company�� principal product is Alpharadin for the treatment of bone metastases resulting from castration-resistant prostate cancer. The Company�� pipeline also includes Alpharadin for the treatment of bone metastases resulting from breast cancer, a combination of Alpharadin with Taxotere for the treatment of bone metastases resulting from prostate cancer and Thorium-227 showing various cancer indications. The Company develops Alpharadin in a development and marketing cooperation with Bayer Schering Pharma. Algeta ASA is active through the two wholly owned subsidiaries, Algeta Innovations AS and Algeta UK Limited. On April 12, 2012, the Company announced that it estabilished a subsidiary active in the United States, Algeta US.

5 Best Tech Stocks To Buy For 2014: Neurocrine Biosciences Inc.(NBIX)

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company?s products in clinical development include Elagolix, a Phase II drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; GnRH Antagonists for men?s and women?s health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize Indiplon in Japan; Abbott International Luxembourg S.�r.l. to develop and commercialize elagolix and GnRH antagonists for women?s and men?s health indications; and Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of type II diabetes and other indications. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By Roberto Pedone]

  Another stock that's starting to trend within range of triggering a major breakout trade is Neurocrine Biosciences (NBIX), which discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. This stock has been a hot name with bulls so far in 2013, with shares up 57%.

  If you look at the chart for Neurocrine Biosciences, you'll notice that this stock recently gapped down sharply from $16.74 to below $11.50 a share with heavy downside volume flows. Following that gap down, shares of NBIX went on to continue its trend lower and the stock hit a new low of $10.42 a share. Shares of NBIX have started to rebound off that $10.42 low and it's now moving within range of triggering a major breakout trade.

  Traders should now look for long-biased trades in NBIX if it manages to break out above some near-term overhead resistance levels at its 200-day moving average of $11.92 a share and above its gap down day high of $12.17 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 894,145 shares. If that breakout triggers soon, then NBIX will set up to re-fill some of its previous gap down zone from September that started at $16.74 a share. Some possible upside targets for NBIX if it gets into that gap with volume are $14 to $15 a share.

  Traders can look to buy NBIX off any weakness to anticipate that breakout and simply use a stop that sits right below support at $11 a share, or below that recent low of $10.42 a share. One can also buy NBIX off strength once it takes out that breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

5 Best Tech Stocks To Buy For 2014: Network Engines Inc(NEI)

Network Engines, Inc. designs and manufactures application platforms and appliance solutions on which software applications are applied for enterprise and telephony information technology networks. The company?s application platforms are pre-configured server-based network infrastructure devices designed to deliver specific software application functionality, and enhance the integration, manageability, and security of that software application in an end user?s network. It also offers platform management software tools and support services related to solution design, systems integration, application management, global logistics, and support and maintenance programs. The company markets its application platform solutions and services to original equipment manufacturers and independent software vendors in the United States and internationally. Network Engines, Inc. was founded in 1989 and is headquartered in Canton, Massachusetts.

Advisors' Opinion:

• [By CRWE]

  NEI (Nasdaq:NEI), a leading provider of server-based application platforms, deployment solutions and lifecycle support services for software technology developers and OEMs worldwide, announced today that it has signed a definitive merger agreement with UNICOM Systems, Inc. (“UNICOM”) and a new UNICOM subsidiary under which UNICOM, a global information technology company and part of the UNICOM group of companies, will acquire NEI for $1.45 per common share in cash.